These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34268373)

  • 1. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.
    Xu X; Fang N; Li H; Liu Y; Yang F; Li X
    Ann Transl Med; 2021 May; 9(9):760. PubMed ID: 34268373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China.
    Yu YF; Luan L; Zhu FF; Dong P; Ma LH; Li LT; Gao L; Lu S
    Front Oncol; 2021; 11():564234. PubMed ID: 34970476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
    Li WQ; Li LY; Chai J; Cui JW
    Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
    Shi Y; Pei R; Liu S
    Front Oncol; 2022; 12():833773. PubMed ID: 36324594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
    Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
    Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer.
    Zhang L; Li N; Liu M; Zheng B; Wu Z; Cai H
    Cancer Manag Res; 2021; 13():4263-4270. PubMed ID: 34093040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (
    Nilsson FOL; Gal P; Houisse I; Ivanova JI; Asanin ST
    J Med Econ; 2021; 24(1):447-457. PubMed ID: 33754924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China.
    Guan H; Wang C; Chen C; Han S; Zhao Z
    Front Oncol; 2022; 12():819674. PubMed ID: 35785198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
    Shu Y; Ding Y; He X; Liu Y; Wu P; Zhang Q
    Front Pharmacol; 2022; 13():920479. PubMed ID: 36204237
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China.
    Shu Y; Zhang Q; He X; Chen L
    Cancer Manag Res; 2021; 13():8297-8306. PubMed ID: 34764692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
    You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS
    PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.
    Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Marti-Bonmati E; Trigo-Vicente C; Cortijo J
    J Comp Eff Res; 2021 Mar; 10(4):325-335. PubMed ID: 33635095
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy.
    Wu B; Gu X; Zhang Q
    J Thorac Oncol; 2018 Feb; 13(2):184-193. PubMed ID: 29101057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
    BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer.
    Li W; Qian L; Li W; Chen X; He H; Tian H; Zhao Y; Wang X; Cui J
    Exp Ther Med; 2021 Apr; 21(4):343. PubMed ID: 33732316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.
    Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Trigo-Vicente C; Cortijo J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):637-646. PubMed ID: 34602008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
    Khoo T; Gao L
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.
    Zeng X; Li J; Peng L; Wang Y; Tan C; Chen G; Wan X; Lu Q; Yi L
    PLoS One; 2014; 9(2):e88881. PubMed ID: 24586426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
    Rui M; Li H
    Clin Ther; 2020 Nov; 42(11):2159-2170.e6. PubMed ID: 33028495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China.
    Mu L; Liu F; Fang Y; He M; Yang M
    BMJ Open; 2024 Aug; 14(8):e081270. PubMed ID: 39179275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.